ToxWipe
Commercial- Indications
- Drug abuse detection
Company intelligence / Profile preview
Oranoxis develops and markets rapid oral fluid and urine-based drug testing devices. Their products are used for qualitative detection of multiple drugs of abuse in various settings including hospitals, laboratories, forensic institutions, employers’ workplaces, and home care. The company’s solutions adhere to international standards such as AS/NZS 4760:2019 CE and ISO 13485. No clinical trial pipeline or investigational therapeutics; focus is on commercialized diagnostics. No published clinical trial results or novel therapeutic programs were found in public databases as of June 2025.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Oranoxis.